Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs
Authors' conclusion
The overall risk of neuroinflammatory events among new users of TNF inhibitors did not differ substantially as compared with new users of other b/tsDMARDs.
Study context
- Population
- Patients with RA, psoriasis, PsA, AS, Crohn's disease or ulcerative colitis initiating b/tsDMARDs, US electronic health records database
- Participants
- 132,015 patients
- Exposure
- TNFi vs other b/tsDMARDs
- Tumor necrosis factor (TNF) inhibitorn = 93,661
- Non-TNFn = 38,354reference
- Outcome
- Neuroinflammatory adverse events
- Follow-up
- 3-year period
Methodological detailsnew user design, US-based electronic health records database
- New user design
- US-based electronic health records database
Main finding
Neuroinflammatory events
Hazard ratio
1.01
95% CI 0.75–1.36
By group
TNF inhibitorvs Non-TNF
HR 1.01 (95% CI 0.75–1.36)
As reported in the abstract
Observational data: associations, not effects.
Further findings
- No significant association between TNF exposure and neuroinflammatory events within each disease group
Original publication
Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken). Published 2 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →